Review Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature Dimitrios Volanis, David E. Neal, Anne Y. Warren and Vincent J. Gnanapragasam Department of Urology, Addenbrooke's University Hospital, Cambridge, UK
With the widespread clinical use of prostate-specific antigen (PSA), biopsy of the prostate has become one of the most commonly performed urological procedures. In general it is well tolerated, although there is some morbidity and risk of infection. In recent years, there have been increasing concerns that prostate biopsy may lead to tumour seeding along the needle tract. The aim of the present paper was to review the evidence on the prevalence of tumour seeding after prostate biopsy and to define the risk of this event in the context of current clinical practice. A PubMed literature search was conducted in January 2014 according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. Literature was examined with emphasis on the incidence of seeding, clinical presentation and on risk factors including type of needle used, transrectal vs transperineal approach, as well as tumour grade and stage. In all, 26 publications were identified reporting needle-tract seeding after prostate biopsy. In all, 42 patients with
Introduction Prostate cancer is the most common malignancy in men and a leading cause of cancer-related morbidity. In Europe it is the third most common neoplasm with 417 000 new cases in 2012 [1]. In the UK it represents 25% of all male neoplasms [2]. Presently the clinical diagnosis of prostate cancer is based on DRE, serum concentration of PSA, and TRUS-guided biopsy of the prostate (TRUS-Bx). In recent years, multiparametric MRI of the prostate has emerged as a non-invasive method for the detection of prostate cancer. The definite diagnosis of prostate cancer depends on the histopathological verification of cancer in prostate biopsy cores or surgical specimens. During the last two decades the number of prostate biopsies taken has increased considerably and it is estimated that >1 million procedures are performed © 2014 The Authors BJU International © 2014 BJU International | doi:10.1111/bju.12849 Published by John Wiley & Sons Ltd. www.bjui.org
needle-tract seeding were identified. In most cases, seeding was reported after transperineal biopsy of the prostate, while nine cases occurred after transrectal biopsy. Based on the reviewed series the incidence of seeding appears to be
With the widespread clinical use of prostate-specific antigen (PSA), biopsy of the prostate has become one of the most commonly performed urological procedures. In general it is well tolerated, although there is some morbidity and risk of infection. In recent years, there have been increasing concerns that prostate biopsy may lead to tumour seeding along the needle tract. The aim of the present paper was to review the evidence on the prevalence of tumour seeding after prostate biopsy and to define the risk of this event in the context of current clinical practice. A PubMed literature search was conducted in January 2014 according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. Literature was examined with emphasis on the incidence of seeding, clinical presentation and on risk factors including type of needle used, transrectal vs transperineal approach, as well as tumour grade and stage. In all, 26 publications were identified reporting needle-tract seeding after prostate biopsy. In all, 42 patients with
Introduction Prostate cancer is the most common malignancy in men and a leading cause of cancer-related morbidity. In Europe it is the third most common neoplasm with 417 000 new cases in 2012 [1]. In the UK it represents 25% of all male neoplasms [2]. Presently the clinical diagnosis of prostate cancer is based on DRE, serum concentration of PSA, and TRUS-guided biopsy of the prostate (TRUS-Bx). In recent years, multiparametric MRI of the prostate has emerged as a non-invasive method for the detection of prostate cancer. The definite diagnosis of prostate cancer depends on the histopathological verification of cancer in prostate biopsy cores or surgical specimens. During the last two decades the number of prostate biopsies taken has increased considerably and it is estimated that >1 million procedures are performed © 2014 The Authors BJU International © 2014 BJU International | doi:10.1111/bju.12849 Published by John Wiley & Sons Ltd. www.bjui.org
needle-tract seeding were identified. In most cases, seeding was reported after transperineal biopsy of the prostate, while nine cases occurred after transrectal biopsy. Based on the reviewed series the incidence of seeding appears to be
